Table 1 Baseline characteristics of eligible studies
Authors | Publication year | Country | Cancer type | Sample size | Follow-up months | Detection method | Clinical outcomes | Analysis method | NOS |
|---|---|---|---|---|---|---|---|---|---|
Chen et al. [27] | 2017 | China | Cervical cancer | 120 | 60 | qRT-PCR | OS | Multivariate | 7 |
Ding et al. [18] | 2015 | China | CRC | 48 | – | qRT-PCR | – | Multivariate | 6 |
Eideet al. [16] | 2019 | Norway | CRC | 1265 | 60 | qRT-PCR | RFS | Multivariate | 7 |
He et al. [25] | 2016 | China | Bladder cancer | 55 | – | qRT-PCR | – | Multivariate | 6 |
Li et al. [31] | 2018 | China | CRC | 157 | 100 | qRT-PCR | OS, DFS | Multivariate | 7 |
Ni et al. [28] | 2016 | China | VSCC | 16 | – | qRT-PCR | – | Multivariate | 6 |
Nie et al. [24] | 2016 | China | Gastric cancer | 42 | 40 | qRT-PCR | OS | Multivariate | 6 |
Qin et al. [22] | 2018 | China | LUAD | 112 | 85 | qRT-PCR | OS | Multivariate | 7 |
Ren , et al. [30] | 2017 | China | ESCC | 185 | 60 | qRT-PCR | OS | Multivariate | 6 |
Shih et al. [4] | 2017 | China | OSCC | 42 | 40 | RNA-seq | OS, RFS | Multivariate | 7 |
Sun et al. [29] | 2018 | China | ESCC | 53 | – | qRT-PCR | – | Multivariate | 6 |
Sun et al. [14] | 2019 | China | Osteosarcoma | 40 | – | qRT-PCR | – | Multivariate | 6 |
Wang et al. [35] | 2018 | China | LSCC | 60 | 85 | qRT-PCR | OS, RFS | Multivariate | 7 |
Wu et al. [40] | 2019 | China | NSCLC | 50 | 85 | qRT-PCR | OS | Multivariate | 8 |
Yan et al. [5] | 2018 | China | HCC | 42 | 25 | qRT-PCR | OS | Multivariate | 7 |
Yang et al. [32] | 2016 | China | CRC | 178 | 70 | qRT-PCR | OS, DFS | Multivariate | 7 |
Zheng et al. [2] | 2019 | China | NSCLC | 88 | 50 | qRT-PCR | OS | Multivariate | 8 |